Mesenchymal Stem Cells for Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01730547|
Recruitment Status : Unknown
Verified January 2015 by Ellen Iacobaeus, Karolinska Institutet.
Recruitment status was: Recruiting
First Posted : November 21, 2012
Last Update Posted : January 15, 2015
Information provided by (Responsible Party):
Ellen Iacobaeus, Karolinska Institutet
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||December 2015|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.